sb 203580 has been researched along with pyrimethamine in 1 studies
| Studies (sb 203580) | Trials (sb 203580) | Recent Studies (post-2010) (sb 203580) | Studies (pyrimethamine) | Trials (pyrimethamine) | Recent Studies (post-2010) (pyrimethamine) |
|---|---|---|---|---|---|
| 3,489 | 4 | 1,137 | 5,088 | 738 | 1,047 |
| Protein | Taxonomy | sb 203580 (IC50) | pyrimethamine (IC50) |
|---|---|---|---|
| Dihydrofolate reductase | Homo sapiens (human) | 3.1057 | |
| Dihydrofolate reductase | Bos taurus (cattle) | 0.1007 | |
| Beta-hexosaminidase subunit alpha | Homo sapiens (human) | 6.8333 | |
| Beta-hexosaminidase subunit beta | Homo sapiens (human) | 6.4 | |
| Dihydrofolate reductase | Escherichia coli K-12 | 4.3 | |
| Bifunctional dihydrofolate reductase-thymidylate synthase | Plasmodium falciparum K1 | 0.0609 | |
| Dihydrofolate reductase | Pneumocystis carinii | 3.25 | |
| Dihydrofolate reductase | Candida albicans | 5 | |
| Low molecular weight phosphotyrosine protein phosphatase | Homo sapiens (human) | 15.615 | |
| Dipeptidyl peptidase 4 | Homo sapiens (human) | 0.39 | |
| Bifunctional dihydrofolate reductase-thymidylate synthase | Toxoplasma gondii | 0.3217 | |
| Bifunctional dihydrofolate reductase-thymidylate synthase | Plasmodium falciparum 3D7 | 2.48 | |
| Dihydrofolate reductase | Rattus norvegicus (Norway rat) | 2.0727 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brumlik, MJ; Burow, ME; Curiel, TJ; Daniel, BJ; Khan, IA; Siekierka, J; Wadsworth, S; Wei, S; Zou, W | 1 |
1 other study(ies) available for sb 203580 and pyrimethamine
| Article | Year |
|---|---|
Drugs designed to inhibit human p38 mitogen-activated protein kinase activation treat Toxoplasma gondii and Encephalitozoon cuniculi infection.
Topics: Animals; Antiprotozoal Agents; CD8 Antigens; Dose-Response Relationship, Drug; Drug Design; Drug Synergism; Drug Therapy, Combination; Encephalitozoon cuniculi; Encephalitozoonosis; Enzyme Inhibitors; Female; Humans; Imidazoles; Mice; Mice, Inbred C57BL; Mice, Inbred CBA; Mice, Knockout; p38 Mitogen-Activated Protein Kinases; Pyridines; Time Factors; Toxoplasma; Toxoplasmosis, Animal | 2007 |